Please assess the completion status of the following clinical trial:

Trial Title: Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Group 1 Inclusion Criteria:~* HIV-uninfected males or females age 18-50 years old~* Willing to maintain low risk behavior for HIV infection~Group 1 Exclusion Criteria:~* confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease and clinically significant laboratory abnormalities~Group 2 Inclusion Criteria:~* HIV-infected males or females age 18-65 years old~* On a stable antiretroviral regimen with HIV-1 RNA plasma level \<50 copies/ml, CD4 cell count greater than or equal to 300 cells/uL~Group 2 Exclusion Criteria:~* history of AIDS-defining illness within the previous 5 years, significant acute or chronic medical condition other than HIV infection, and clinically significant laboratory abnormalities~Group 3 Inclusion Criteria:~* HIV-infected males or females age 18-65~* Not on antiretroviral therapy for \> 6 months with detectable HIV-1 viral load between 100 and 100,000 copies/ml, CD4 cell count greater than or equal to 300 cells/uL~Group 3 Exclusion Criteria:~* history of AIDS-defining illness within the previous 5 years, significant acute or chronic medical condition other than HIV infection, and clinically significant laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1A (Type: EXPERIMENTAL): HIV-uninfected participants
- Group 1B (Type: EXPERIMENTAL): HIV-uninfected participants
- Group 1C (Type: EXPERIMENTAL): HIV-uninfected participants
- Group 2A (Type: EXPERIMENTAL): HIV-infected on ART, (\<50 cp/ml)
- Group 2B (Type: EXPERIMENTAL): HIV-infected on ART, (\<50 cp/ml)
- Group 2C (Type: EXPERIMENTAL): HIV-infected on ART, (\<50 cp/ml)
- Group 3A (Type: EXPERIMENTAL): HIV-Infected off ART (VL 2x10\^3 - 1x10\^5 cp/ml)
- Group 3B (Type: EXPERIMENTAL): HIV-Infected off ART (VL 1x10\^2 - 2x10\^3 cp/ml)
- Arm 1D (Type: EXPERIMENTAL): HIV-uninfected participants

Based on this trial design, predict the completion outcome and termination type (if applicable).